FDA Clears First At-Home Cervical Cancer Screening Device: A New Era in Women’s Health

3 min read

A groundbreaking self-collection tool, the Teal Wand, has won FDA approval—offering a comfortable, accurate alternative to the traditional Pap smear and reshaping how women access preventive care.

A sleek photorealistic horizontal header image of the Teal Wand device—light teal wand with sponge-like tip—resting beside a neatly packed at‑home screening kit on a clean white surface, with soft natural lighting, professional medical aesthetic, no logos or text.

</div>

1. A Milestone in Cervical Cancer Prevention

On May 9, 2025, the FDA granted De Novo authorization to Teal Health’s Teal Wand, the first and only at-home self‑collection device for cervical cancer screening in the U.S. . The device enables individuals aged 25 to 65 to collect vaginal samples at home and mail them to a lab for HPV testing using the same Roche cobas® assay used in clinics .

2. Clinical Validation and User Preference

In the SELF‑CERV nationwide clinical study, the Teal Wand demonstrated equivalent sensitivity to clinician‑collected samples—detecting cervical precancer (CIN2+) 96% of the time . Additionally, 86% of study participants said they'd be more likely to stay up-to-date with screening if they could do it at home, and 94% preferred self-collection when assured of accuracy .